AT Bancorp’s Regeneron Pharmaceuticals REGN Stock Holding History

AT Bancorp’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,598	Closed	-$550K	–	240
2018 Q1	$550K	Buy	+1,598	New	+$556K	0.06%	154

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AT Bancorp's REGN Position: Q2 2018 in Review

AT Bancorp sold out of Regeneron Pharmaceuticals (REGN) in Q2 2018, closing a stake of 1,598 shares — an estimated $550K sold.

AT Bancorp first reported a position in REGN in Q1 2018 and held it in 1 quarter. The position peaked at $550K in Q1 2018. 624 funds tracked by Wall St. Rank hold REGN as of Q2 2018.

AT Bancorp reported no remaining Regeneron Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
AT Bancorp sold 1,598 Regeneron Pharmaceuticals shares in Q2 2018, an estimated $550K.
AT Bancorp first reported a position in Regeneron Pharmaceuticals in Q1 2018 and held it in 1 quarter.
AT Bancorp's Regeneron Pharmaceuticals position peaked at $550K in Q1 2018.
624 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2018.

Based on AT Bancorp's 13F filing for Q2 2018, filed 8 Aug 2018.